Compare · ARGX vs EXEL
ARGX vs EXEL
Side-by-side comparison of argenx SE (ARGX) and Exelixis Inc. (EXEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and EXEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $49.78B, about 4.1x EXEL ($12.20B).
- Over the past year, ARGX is up 40.9% and EXEL is up 21.0% - ARGX leads by 19.9 points.
- EXEL has been more active in the news (22 items in the past 4 weeks vs 6 for ARGX).
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Exelixis Inc.
- Price
- $812.95+1.32%
- $51.60+6.35%
- Market cap
- $49.78B
- $12.20B
- 1M return
- +0.24%
- +16.94%
- 1Y return
- +40.88%
- +21.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2000
- News (4w)
- 6
- 22
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest EXEL
- Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
- Director Papadopoulos Stelios was granted 8,367 shares, increasing direct ownership by 0.70% to 1,197,595 units (SEC Form 4)
- Director Eckhardt Sue Gail was granted 8,367 shares, increasing direct ownership by 48% to 25,891 units (SEC Form 4)
- Director Heyman Tomas J. was granted 8,367 shares, increasing direct ownership by 20% to 50,649 units (SEC Form 4)
- Director Smith Julie was granted 8,367 shares, increasing direct ownership by 41% to 28,957 units (SEC Form 4)
- Director Freire Maria C was granted 8,367 shares, increasing direct ownership by 8% to 109,186 units (SEC Form 4)
- Director Beckerle Mary C was granted 8,367 shares, increasing direct ownership by 48% to 25,891 units (SEC Form 4)
- Director Oliver Bob was granted 8,367 shares, increasing direct ownership by 40% to 29,487 units (SEC Form 4)
- Director Wyszomierski Jack L was granted 8,367 shares, increasing direct ownership by 3% to 288,309 units (SEC Form 4)
- Director Poste George was granted 8,367 shares, increasing direct ownership by 7% to 127,199 units (SEC Form 4)